Lupin Posts S&P Global ESG Rating of 91 in 2025

Global pharma leader Lupin Limited (Lupin) has announced that it has achieved an S&P Global ESG Score of 91 for 2025, well above the pharmaceutical industry average of 28. Lupin is now part of an exclusive group of companies worldwide that have surpassed the 90-point mark.*

This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth.

Ramesh Swaminathan, Executive Director, Global CFO, and Head of IT and API Plus SBU, Lupin, said, “Achieving a score above 90 in the S&P Global ESG ratings is rare global distinction, highlighting our unwavering commitment to sustainability. With a 15-point increase from last year, Lupin not only leads the pharmaceutical industry today, but redefines and sets new standards for responsible growth. Our purpose-led strategy ensures that we provide healthcare solutions that generate lasting value for patients, communities, and stakeholders worldwide.” 

Lupin has made significant progress across all three pillars - Environmental, Social, and Governance. The company has intensified its environmental efforts by increasing the use of renewable energy, successfully reducing carbon emissions, and achieving water-positive operations. On the social front, Lupin has prioritized employee well-being by promoting diversity and inclusion, launching community health programs, and making significant contributions to societal healthcare. In terms of governance, the organization has enhanced transparency, upheld ethical business practices, fortified corporate governance, and instituted board-level oversight to address ESG-related risks and opportunities effectively.